Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy

Table 2 Patient characteristics according to gonadotropin-releasing hormone agonist treatment in equal to or younger than 35 years patients

Variable	GnRH agonist (n = 30), n (%)	No. of GnRH agonist (n = 48), n (%)	P value
BMI			0.999
≤ 25	25 (83.33)	40 (83.33)
> 25	5 (16.67)	8 (16.67)
Clinical tumor stage			0.150
cT1	2 (6.67)	6 (12.50)
cT2	13 (43.33)	23 (47.92)
cT3	14 (46.67)	12 (25.00)
cT4	1 (3.33)	7 (14.58)
Clinical node stage			0.185
cN1	8 (26.67)	6 (12.50)
cN2	12 (40.00)	28 (58.33)
cN3	10 (33.33)	14 (29.17)
Pathologic tumor stage			0.706
ypT0-is	7 (23.33)	8 (16.67)
ypT1	8 (26.67)	15 (31.25)
ypT2	8 (26.67)	17 (35.42)
ypT3	7 (23.33)	8 (16.67)
ypT4	0 (0.00)	0 (0.00)
Pathologic node stage			0.061
ypN0	9 (30.00)	16 (33.33)
ypN1	10 (33.33)	20 (41.67)
ypN2	7 (23.33)	11 (22.92)
ypN3	4 (13.33)	1 (2.08)
Lymphovascular invasion			0.754
Present	13 (43.33)	25 (52.08)
Absent	14 (46.67)	18 (37.50)
Unknown	3 (10.00)	5 (10.42)
Surgery			0.472
Breast conserving	15 (50.00)	28 (58.33)
Mastectomy	15 (50.00)	20 (41.67)
Nuclear grade			0.984
Low	4 (13.33)	7 (14.58)
Intermediate	13 (43.33)	19 (39.58)
High	10 (33.33)	17 (35.42)
Unknown	3 (10.00)	5 (10.42)
Radiation therapy			0.555
Yes	28 (93.33)	47 (97.92)
No	2 (6.67)	1 (2.08)

GnRH: Gonadotropin-releasing hormone; BMI: Body mass index.